MapLight Therapeutics (MPLT)
Develops circuit-selected medicines for central nervous system disorders through a clinical-stage pipeline.
Something off on this page? Send us feedback.
Develops clinical-stage medicines for central nervous system disorders using optogenetics, single-cell transcriptomics, and STARmap to select and validate circuit-specific drug targets. The pipeline includes Phase 2 programs in schizophrenia, Alzheimer’s disease psychosis, and autism spectrum disorder, with no commercial products yet and progress tied to clinical and regulatory execution.
Develops clinical-stage medicines for central nervous system disorders, pairing a circuit-neuroscience discovery platform with a pipeline led by ML-007C-MA and ML-004. The platform combines optogenetics, single-cell transcriptomics, and STARmap spatial transcriptomics to identify and validate targets linked to defined neural circuits.
Current clinical work includes Phase 2 programs in schizophrenia, Alzheimer’s disease psychosis, and autism spectrum disorder. Target selection and spatial validation are designed to connect disease-related behaviors with pharmacological intervention, while global development and commercial rights have been retained across the portfolio.
Operations are based in Redwood City, with no commercial products yet. Progress depends on clinical trials, regulatory review, third parties, intellectual-property protection, specialized personnel, and continued access to capital.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 31, 2026 | Needham | Reiterate | Buy | $45 | $43 | |
| Aug 14, 2026 | Canaccord Genuity | Target | $24 | $21 | ||
| Aug 14, 2026 | Raymond James | Target | $46 | $31 | ||
| Aug 10, 2026 | UBS | Downgrade | Buy | Neutral | $52 | $13 |
| Jul 28, 2026 | Craig-Hallum | Reiterate | Buy | $40 | $25 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $304.7M · Total debt $2.0M · Total assets $368.3M · Shareholders' equity $348.3M
- Revenue
- $0
- Operating income
- −$63.5M
- Net income
- −$60.2M
No dividends on record.
| Institutions110 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | ≈ 116.41% | 52.78M shares | |
| Adds to | 116.41% |
45.35M company shares as of Sep 3, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 116.41%; nothing is left for Other.
This company has 2 share classes; every stake here is a share of the whole company.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Novo Holdings A/SInstitution | 16.26% | 3.69M · 3.69M | 13Fas of Jun 30, 2026 |
FCPM Iii Services B.V.Institution | 14.23% | 3.23M · 3.23M | 13Fas of Jun 30, 2026 |
T. Rowe Price Investment Management, Inc.Institution | 12.27% | 2.78M · 2.78M | 13Fas of Jun 30, 2026 |
Goldman Sachs Group IncInstitution | 8.59% | 1.95M · 1.95M | 13Fas of Jun 30, 2026 |
Price T Rowe Associates Inc /MD/Institution | 6.28% | 1.42M · 1.42M | 13Fas of Jun 30, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings
Insider tradesForm 4
Nothing filed in the last 12 months.
- Bristol-Myers Squibb
Commercial and pipeline rival in M1/M4 neuropsychiatric therapies
- Neurocrine Biosciences
Develops muscarinic agonists for schizophrenia and other brain disorders
- AbbVie
Commercial schizophrenia rival with an active M4 pipeline
- Acadia Pharmaceuticals
Head-to-head Phase 2 rival in Alzheimer's disease psychosis
- Neumora Therapeutics
Advances an oral M4 PAM for schizophrenia
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| MapLight Therapeutics | $13.06 | −1.88% | $554.2M | — | — | — | — |
| Bristol-Myers Squibb | $67.64 | −0.02% | $138.21B | 14.9 | 10.6 | 2.8 | +5.7% |
| Neurocrine Biosciences | $157.77 | +0.64% | $15.87B | 23.1 | 17.3 | 4.7 | +39.5% |
| AbbVie | $261.07 | −0.24% | $462.37B | 73.7 | 17.2 | 7.2 | +10.2% |
| Acadia Pharmaceuticals | $28.93 | −0.03% | $4.95B | 13.0 | 32.5 | 4.4 | +16.4% |
| Neumora Therapeutics | $1.38 | +3.38% | $255.7M | — | — | — | — |
| Median | 19.0 | 17.3 | 4.5 | +13.3% |